Prospects rose for Galapagos and partner Gilead's JAK1 inhibitor with impressive Phase III FINCH 2 data in patients with moderate-to-severe rheumatoid arthritis.
More evidence supporting Gilead Sciences Inc. and its partner Galapagos NV's jointly developed JAK1 selective kinase inhibitor has come in the form of positive results from filgotinib's first pivotal trial in rheumatoid arthritis - results that analysts say effectively de-risk the investigational therapy.
Filgotinib, which is being developed for multiple indications, achieved the primary endpoint in the FINCH 2 late-stage study evaluating it...
The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.
Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.
Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.
The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.
The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.
In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.
The Phase III failure could dent Roche’s hopes of entering the COPD market with its novel therapy, despite its success in a large Phase IIb trial. It also marks another disappointment for the anti-IL33/ST2 approach.
